Experts make weak recommendation for remdesivir in severe COVID-19

July 30, 2020

In The BMJ today, a panel of international experts make a weak recommendation for the use of remdesivir in patients with severe covid-19, and strongly support continued enrolment of patients into ongoing clinical trials of remdesivir.

Their advice is part of The BMJ's Rapid Recommendations initiative - to produce rapid and trustworthy guidelines for clinical practice based on new evidence to help doctors make better decisions with their patients.

The antiviral medication remdesivir has received worldwide attention as a potentially effective treatment for severe covid-19 and is already being used in clinical practice.

Today's recommendation is based on a new evidence review comparing the effects of several drug treatments for covid-19 up to 20 July 2020.

It shows that remdesivir may be effective in reducing recovery time in patients with severe covid-19, although the certainty of the evidence is low. But remdesivir probably has no important effect on the need for mechanical ventilation and may have little or no effect on length of hospital stay.

The authors stress that "the effectiveness of most interventions is uncertain because most of the randomised controlled trials so far have been small and have important study limitations."

After thoroughly reviewing this evidence, the expert panel says that most patients with severe covid-19 would likely choose treatment with remdesivir given the potential reduction in time to clinical improvement.

But given the low certainty evidence, and allowing for different patient perspectives, values, and preferences, they issued a weak recommendation with strong support for continued recruitment in trials.

They suggest that future research should focus on areas such as optimal dose and duration of therapy, and whether there are specific groups of patients most likely to benefit from remdesivir.

The authors also sound a note of caution about the potential opportunity cost of using remdesivir while the evidence base is still uncertain. As a relatively costly drug that is given intravenously, use of remdesivir may divert funds, time, attention, and workforce away from other potentially worthwhile treatments.

The study that today's recommendation is based on is called a living systematic review.

In a linked editorial, The BMJ editors explain that living systematic reviews are useful in fast moving research areas such as covid-19 because they allow authors to update previously vetted and peer reviewed evidence summaries as new information becomes available.

This is the second living systematic review published by The BMJ this year, and it will be updated to reflect emerging evidence. Several more are planned, including one on pregnancy outcomes among women infected with covid-19.
-end-
Peer reviewed? Yes (research, clinical guideline), No (editorial)

Evidence type: Living systematic review; clinical practice guideline, editorial

Subjects: Drugs for covid-19

BMJ

Related Authors Articles from Brightsurf:

Representation of female authors in family medicine academic journals is trending upward
After decades of underrepresentation in medicine, women are now entering many specialties in the United States, including family medicine, at higher rates than men.

Comparing proportions of female, male corresponding authors in preprint research repositories before, during COVID-19 pandemic
Researchers examined changes in the proportion of female corresponding authors in bioRxiv (biorxiv.org) and medRxiv (medrxiv.org), which are online archive and distribution services for unpublished preprint research in the life and health sciences, respectively, before and during the COVID-19 pandemic.

Authors' 'invisible' words reveal blueprint for storytelling
The ''invisible'' words that shaped Dickens classics also lead audiences through Spielberg dramas.

Only 1 in 3 COVID-19 research authors are women and even fewer are senior authors
Women make up only a third of all authors who have published research on COVID-19 since the beginning of the pandemic in January this year, and even fewer of them are senior authors on these papers, suggests an analysis in BMJ Global Health.

TOS president-elect co-authors study on genetic test for obesity
President-elect of The Obesity Society (TOS) Lee M. Kaplan, MD, PhD, FTOS, has co-authored a new study that describes a newly developed genetic test that can identify newborns at the highest risk of developing severe obesity, the Society announced today.

Cell lines deserve unique considerations when creating research protections, authors say
New rules recently went into effect, seeking to protect patients who donate tissue samples for research in the age of genetic sequencing.

UM professor co-authors report on the use of biotechnology in forests
University of Montana Professor Diana Six is one of 12 authors of a new report that addresses the potential for biotechnology to provide solutions for protecting forest trees from insect and pathogen outbreaks, which are increasing because of climate change and expanded global trade.

Articles provide updated guidance to authors submitting to the British Journal of Pharmacology
New editorials published in the British Journal of Pharmacology provide guidance for authors of papers submitted to the journal, with guidance on how to design and conduct experiments as well as what key information should be provided in methodology and presentation of data.

Temperature resilient crops now an 'achievable dream' say authors of new study
Breeding temperature-resilient crops is an 'achievable dream' in one of the most important species of commercially cultivated plants, according to a new study.

Journal of Dairy Science® honors most prolific authors
As part of the centennial celebration for the Journal of Dairy Science, individuals who have authored or coauthored 100 or more papers in the journal will be inaugurated into JDS Club 100 at the 2017 American Dairy Science Association® Annual Meeting in Pittsburgh, Pa.

Read More: Authors News and Authors Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.